Systems-level approaches to discover host-targeted repurposable drugs against SARS-CoV-2 infection
Development of candidate anti-infectives identified by Artificial Intelligence (AI).
The UPDDI is participating in a COVID19-related project aimed at discovering potential new treatments for the disease through a collaborative effort by research groups at the University of Pittsburgh Department of Computational and Systems Biology, the University of California, Los Angeles (UCLA), and Cedars Sinai Hospital. Through a series of sophisticated mathematical and artificial intelligence-based methods, the team identified a number of potential candidates that were tested in the laboratory for inhibition of SARS-CoV-2 infection and cellular entry. The most promising candidates are currently being considered for further development into potential COVID19 therapies.
Papers
Chen F, Shi Q, Pei F, Vogt A, Porritt RA, Garcia G, Jr., Gomez AC, Cheng MH, Schurdak ME, Liu B, Chan SY, Arumugaswami V, Stern AM, Taylor DL, Arditi M, Bahar I. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol Syst Biol. 2021;17(8):e10239. PubMed PMID: 34339582. (open access) http://dx.doi.org/10.15252/msb.202110239
Click here and include “SARS” in the Additional Gift Instructions to support research at the UPDDI to apply AI to identify existing therapeutics to treat COVID-19 infections now and more rapidly identify treatments for future infectious agents.